Be Skeptical About the Long Term<br />By Rev Shark<br />RealMoney.com Contributor<br />12/10/2007 7:51 AM EST <br /><br /><br />The first proof of a person's incapacity to achieve, is their endeavoring to fix the stigma of failure on others. <br />-- B. R. Hayden<br /><br />Concerns about a looming recession and continued fallout from the subprime mortgage mess are in the headlines every day lately. The popular press is downright gloomy as it discusses the problems and gives us plenty of anecdotal evidence of how bad things really are. Nonetheless, the market continues to hold up as it looks to governmental efforts to find some ways to fix the problems. <br /><br />Last week, a "bailout" program from borrowers who fall within a narrow set of parameters was announced and helped to bolster the market mood. This week, the market is looking toward the Federal Open Market Committee's interest rate decision on Tuesday afternoon to further brighten the mood and give us more relief from the liquidity squeeze. <br /><br />The question we need to consider is how long these government efforts to fix economic problems can continue to hold the market up. Many wonder whether any of the actions that are being taken can really fix problems that have a root cause far deeper than the level of interest rates. Freezing and/or cutting rates will only help bail out a fairly small group of troubled loans. Many loans will still need to be digested by the financial system in one way or another, and there is going to be some economic fallout regardless of what remedies are embraced. <br /><br />Is the market is being overly optimistic about the impact of these governmental efforts, or have we already priced in the problems and a potential recession? Is the worst already fully discounted by the market? That seems like a very questionable proposition. <br /><br />In the short term we have the Fed decision and positive seasonality into the end of the year to help us out. A lot of big money needs to hold this market up into the end of the year, and, with the help of the Fed, those players are going to do their best to keep things from falling apart. You don't have to be a believer in the health of this market to understand why we may continue to hold up as the year winds down. <br /><br />The key for the individual investor is to be very hesitant about trusting in the longer-term health of the market at this point. The shorter-term positives can help us overlook some very major problems, but at some point the market is going to pay a price if an economic slowdown is coming, as looks increasingly likely. <br /><br />Today and tomorrow we are going to be held hostage by the Fed interest rate decision. That is all that matters at the moment. After that, things will get very tricky once again, but seasonality may save us for a few more weeks. <br /><br />We have positive early indications this morning. Asian markets were mostly lower and Europe was mixed overnight. UBS (UBS) announced a large subprime writedown, but that isn't having much of an impact in the early going.<br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance/same store sales: FREE +3.0%, MCD +1.4%... M&A news: ARXT +35.7% (announces Reckitt Benckiser will tender for acquisition of ARXT for $60/share in cash), MOGN +20.2% (Eisai to acquire MOGN for $41/share in an all cash transaction), PLTE +6.0% (to be acquired for $23.50 per share)... Other news: GTCB +19.6% (obtains FDA Orphan Drug Designation for Atryn), LDK +15.8% (signs a 10-year wafer supply agreement with Q-Cells), NVAX +13.9% (NVAX and GE Healthcare establish collaboration to develop and market pandemic influenza solution), OSIR +7.9% (receives FDA fast track status for Prochymal as first-line treatment for Acute GvHD), KEG +6.4% (announced that it has acquired the well service assets of Kings Oil Tools, acquired assets will contribute revenue of approximately $36 mln in 2008), SGEN +6.4% (announces positive data from a phase Ia trial of SGN-33), EPCT +4.9% (releases new data demonstrating prolonged five-year leukemia-free survival for AML patients treated with Ceplene + IL-2), PHG +4.5% (Philips shares rise as hedge funds review co - Bloomberg.com), WCI +3.7% (obtains bank covenant waiver extension), NICE +3.4% (CIBC is nudging ests and see the current weakness as a major buying opportunity), MLNM +3.3% (reported complete remission rate of 35% achieved in a Phase 3 front-line multiple myeloma trial with Velcade for injection based therapy), QCCO +2.8% (announces $2.50 special cash dividend through leveraged recapitalization), LZB +2.8% (receives $7.1 mln under U.S. dumping act), UBS +2.5% (gains two new investors, write down $10 bln), CDE +2.0% (approves merger with Bolnisi Gold and Palmarejo).<br /><br />Allapoole avanevad:<br /><br />In reaction to weak earnings/guidance: NAVI -4.0%, HIG -3.1%, HAYZ -3.2%... Other news: AMC -41.4% (announces adjusted funds from operations per share guidance is no longer a relevant forecast and is withdrawn; co also cancels dividend), TIN -20.8% (today is ex-dividend date for special $10.25 dividend), HEB -18.6% (intends to terminate license to Esteve for marketing of Ampigen in certain territories), SGMO -4.1% (announces presentation of positive data from its novel cell therapy), CELG -3.5% (announces Phase III Trial results of Revlimid), KOSN -2.8% (announces updated data on Tanespimycin), EXAR -2.6% (resignation of CEO a 'big blow' to turnaround efforts - CIBC), GEOY -1.5% (Harbinger Group lowers stake to 6.3% from 7.6%)... Analyst downgrades: LTRE -4.6% (downgraded to Hold at Stifel), RHT -3.0% (downgraded to Hold at Jefferies), AMGN -2.5% (downgraded to Market Perform at Bernstein, downgraded to Neutral at Merrill), STO -2.0% (downgraded to Hold at Deutsche Securities), VE -1.8% (downgraded to Hold at Brean Murray), VMC -1.1% (initiated with an Sell at UBS).